Journal of Gastroenterology and Hepatology

Volume 22, Issue 9 pp. 1510-1518

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

Jialun Zhou,

Jialun Zhou

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

Gregory J Dore,

Gregory J Dore

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

Fujie Zhang,

Fujie Zhang

Ditan Hospital, Beijing, China;

Search for more papers by this author

Poh Lian Lim,

Poh Lian Lim

Tan Tock Seng Hospital, Singapore; and

Search for more papers by this author

Yi-Ming A Chen,

Corresponding Author

Yi-Ming A Chen

AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan

Dr Yi-Ming Arthur Chen, AIDS Prevention and Research Center, National Yang-Ming University, 155, Li-Noun Street, Sec. 2, Taipei, Taiwan 112. Email: [email protected]Search for more papers by this author

The TREAT Asia HIV Observational Database,

The TREAT Asia HIV Observational Database

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

Jialun Zhou,

Jialun Zhou

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

Gregory J Dore,

Gregory J Dore

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

Fujie Zhang,

Fujie Zhang

Ditan Hospital, Beijing, China;

Search for more papers by this author

Poh Lian Lim,

Poh Lian Lim

Tan Tock Seng Hospital, Singapore; and

Search for more papers by this author

Yi-Ming A Chen,

Corresponding Author

Yi-Ming A Chen

AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan

The TREAT Asia HIV Observational Database,

The TREAT Asia HIV Observational Database

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia;

Search for more papers by this author

First published: 15 August 2007

https://doi.org/10.1111/j.1440-1746.2007.05062.x

Citations: 67

Share a link

Email
Wechat
Bluesky

Abstract

Background and Aim: Most studies of hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection with HIV have been conducted among Western patient populations. This study aims to assess rates of HBV and HCV coinfection, and their impact on response to antiretroviral therapy and mortality, using data from The TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of patients with HIV in the Asia–Pacific region.

Methods: Patients who had been tested either HBV surface antigen (HBsAg) or HCV antibody were included. Patients who ever tested positive for HBV or HCV were regarded as coinfected for the duration of the study.

Results: Results of hepatitis tests were available for 55% (HBV) and 49% (HCV) of 2979 TAHOD patients, with prevalence of HBV and HCV coinfection both at approximately 10%. Mean CD4 change at 180 days after antiretroviral treatment initiation was 118.8 cells/μL and patients with either HBV or HCV had a lower but non-significant CD4 increase compared with patients with HIV only. Median time to reach undetectable viral load (<400 copies/mL) was 148 days and was not independently associated with HBV or HCV. In univariate analysis, patients with HCV had increased mortality (unadjusted hazard ratio, HR 2.80, P = 0.007). However, neither HBV (adjusted HR 0.80, 95% confidence interval CI 0.24–2.64, P = 0.710) nor HCV (adjusted HR 1.06, 95% CI 0.40–2.79, P = 0.905) was associated with increased mortality after adjustment for other covariates. Both HBV and HCV remained independently associated with elevated alanine aminotransferase (ALT) in the multivariate model (HBV, adjusted HR 1.94, 95% CI 1.04–3.62, P = 0.037; HCV, adjusted HR 2.74, 95% CI 1.47–5.12, P = 0.002).

Conclusion: The impact of hepatitis coinfection on immunological and virological responses to antiretroviral therapy and HIV disease progression among this Asian cohort are similar to that seen in Western countries. The longer-term impact of hepatitis coinfection on both HIV disease and liver disease morbidity and mortality needs to be monitored.

References

1 WHO. The World Health Report. Geneva: WHO, 2002.
Google Scholar
2 UNAIDS and WHO. AIDS Epidemic Update (December 2005). Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO), 2005.
Google Scholar
3 WHO. Hepatitis C fact sheet , 2006. Cited 15 May 2006. Available from URL: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html
Google Scholar
4 WHO. Hepatitis B fact sheet , 2000. Cited 15 May 2006. Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en/
Google Scholar
5 Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 2006; 44 (Suppl. 1): S6–9.
10.1016/j.jhep.2005.11.004
PubMed Google Scholar
6 Hogg RS, Heath KV, Yip B et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450–54.
10.1001/jama.279.6.450
CAS PubMed Web of Science® Google Scholar
7 Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–9.
10.1016/S0140-6736(03)13802-0
CAS PubMed Web of Science® Google Scholar
8 Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 2001; 32: 492–7.
10.1086/318501
CAS PubMed Web of Science® Google Scholar
9 Mocroft A, Soriano V, Rockstroh J et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117–25.
10.1097/01.aids.0000194799.43799.ea
PubMed Web of Science® Google Scholar
10 Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol. 1997; 27: 18–24.
10.1016/S0168-8278(97)80274-7
CAS PubMed Web of Science® Google Scholar
11 Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2003; 33: 365–72.
10.1097/00126334-200307010-00011
CAS PubMed Web of Science® Google Scholar
12 Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J. Infect. 2000; 40: 127–31.
10.1053/jinf.1998.0636
CAS PubMed Web of Science® Google Scholar
13 Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003; 4: 241–9.
10.1046/j.1468-1293.2003.00152.x
CAS PubMed Google Scholar
14 Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800–5.
10.1016/S0140-6736(00)03232-3
CAS PubMed Web of Science® Google Scholar
15 De Luca A, Bugarini R, Lepri AC et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch. Intern. Med. 2002; 162: 2125–32.
10.1001/archinte.162.18.2125
CAS PubMed Web of Science® Google Scholar
16 Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199–206.
10.1001/jama.288.2.199
PubMed Web of Science® Google Scholar
17 Law WP, Duncombe CJ, Mahanontharit A et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18: 1169–77.
10.1097/00002030-200405210-00010
PubMed Web of Science® Google Scholar
18 Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 2005; 192: 992–1002.
10.1086/432762
PubMed Web of Science® Google Scholar
19 Braitstein P, Zala C, Yip B et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J. Infect. Dis. 2006; 193: 259–68.
10.1086/498908
CAS PubMed Web of Science® Google Scholar
20 Law WP, Dore GJ, Duncombe CJ et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS 2003; 17: 2191–9.
10.1097/00002030-200310170-00007
CAS PubMed Web of Science® Google Scholar
21 Weber R, Sabin C, Friis-Møller N et al. Exposure to antiretroviral therapy and the risk of liver-related death: is there an association? Results from the D:A:D Study. 13th Conference on Retroviruses and Opportunistic Infections; 2006 February; Denver; 2006.
Google Scholar
22 Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004; 364: 69–82.
10.1016/S0140-6736(04)16593-8
PubMed Web of Science® Google Scholar
23 Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J. Acquir. Immune Defic. Syndr. 2005; 38: 174–9.
10.1097/01.qai.0000145351.96815.d5
PubMed Web of Science® Google Scholar
24 Kumarasamy N, Solomon S, Chaguturu SK et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003; 17: 2267–9.
10.1097/00002030-200310170-00019
PubMed Web of Science® Google Scholar
25 Pujari SN, Patel AK, Naik E et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J. Acquir. Immune Defic. Syndr. 2004; 37: 1566–9.
10.1097/00126334-200412150-00005
CAS PubMed Web of Science® Google Scholar
26 Konopnicki D, Mocroft A, De Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593–601.
10.1097/01.aids.0000163936.99401.fe
PubMed Web of Science® Google Scholar
27 Guitton E, Montastruc JL, Lapeyre-Mestre M. Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur. J. Clin. Pharmacol. 2006; 62: 243–9.
10.1007/s00228-005-0080-0
PubMed Web of Science® Google Scholar
28 Mocroft A, Phillips AN, Soriano V et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res. Hum. Retroviruses 2005; 21: 527–36.
10.1089/aid.2005.21.527
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume22, Issue9

September 2007

Pages 1510-1518

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database

Abstract

References

Citing Literature

References

Related

Information